Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children’s Oncology Group

详细信息    查看全文

• 作者：William Temple ; Lori Mendelsohn…
• 关键词：Neuroblastoma ; Vesicular monoamine transporters ; VMAT1 ; VMAT2 ; MIBG avidity
• 刊名：European Journal of Nuclear Medicine and Molecular Imaging
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：43
• 期：3
• 页码：474-481
• 全文大小：721 KB
• 参考文献：1.Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369(9579):2106–20.PubMed CrossRef
  2.Taggart D, Dubois S, Matthay KK. Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q J Nucl Med Mol Imaging. 2008;52(4):403–18.PubMed
  3.DuBois SG, Matthay KK. Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma. Nucl Med Biol. 2008;35 Suppl 1:S35–48.PubMed PubMedCentral CrossRef
  4.Wilson JS, Gains JE, Moroz V, Wheatley K, Gaze MN. A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma. Eur J Cancer. 2014;50(4):801–15.PubMed CrossRef
  5.Treuner J, Feine U, Niethammer D, Muller-Schaumburg W, Meinke J, Eibach E, et al. Scintigraphic imaging of neuroblastoma with [131-I]iodobenzylguanidine. Lancet. 1984;1(8372):333–4.PubMed CrossRef
  6.Smets LA, Janssen M, Rutgers M, Ritzen K, Buttenhuis C. Pharmacokinetics and intracellular distribution of the tumor-targeted radiopharmaceutical m-iodo-benzylguanidine in SK-N-SH neuroblastoma and PC-12 pheochromocytoma cells. Int J Cancer. 1991;48(4):609–15.PubMed CrossRef
  7.Smets LA, Loesberg C, Janssen M, Metwally EA, Huiskamp R. Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells. Cancer Res. 1989;49(11):2941–4.PubMed
  8.Smets LA, Rutgers M. Model studies on metaiodobenzylguanidine (MIBG) uptake and storage: relevance for 131I-MIBG therapy of neuroblastoma. J Nucl Biol Med. 1991;35(4):191–4.PubMed
  9.Carlin S, Mairs RJ, McCluskey AG, Tweddle DA, Sprigg A, Estlin C, et al. Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors. Clin Cancer Res. 2003;9(9):3338–44.PubMed
  10.DuBois SG, Geier E, Batra V, Yee SW, Neuhaus J, Segal M, et al. Evaluation of norepinephrine transporter expression and metaiodobenzylguanidine avidity in neuroblastoma: a report from the children’s oncology group. Int J Mol Imaging. 2012;2012:250834.PubMed PubMedCentral CrossRef
  11.Mairs RJ, Livingstone A, Gaze MN, Wheldon TE, Barrett A. Prediction of accumulation of 131I-labelled meta-iodobenzylguanidine in neuroblastoma cell lines by means of reverse transcription and polymerase chain reaction. Br J Cancer. 1994;70(1):97–101.PubMed PubMedCentral CrossRef
  12.Lawal HO, Krantz DE. SLC18: Vesicular neurotransmitter transporters for monoamines and acetylcholine. Mol Aspects Med. 2013;34(2-3):360–72.PubMed PubMedCentral CrossRef
  13.Guilloteau D, Baulieu JL, Huguet F, Viel C, Chambon C, Valat C, et al. Meta-iodobenzylguanidine adrenal medulla localization: autoradiographic and pharmacologic studies. Eur J Nucl Med. 1984;9(6):278–81.PubMed CrossRef
  14.Kolby L, Bernhardt P, Levin-Jakobsen AM, Johanson V, Wangberg B, Ahlman H, et al. Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters. Br J Cancer. 2003;89(7):1383–8.PubMed PubMedCentral CrossRef
  15.Fottner C, Helisch A, Anlauf M, Rossmann H, Musholt TJ, Kreft A, et al. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression. J Clin Endocrinol Metab. 2010;95(6):2800–10.PubMed CrossRef
  16.Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, et al. Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013;14(10):999–1008.PubMed PubMedCentral CrossRef
  17.Yanik GA, Parisi MT, Shulkin BL, Naranjo A, Kreissman SG, London WB, et al. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children’s Oncology Group. J Nucl Med. 2013;54(4):541–8.PubMed CrossRef
  18.Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer. 1999;86(2):364–72.PubMed CrossRef
  19.Anlauf M, Eissele R, Schafer MK, Eiden LE, Arnold R, Pauser U, et al. Expression of the two isoforms of the vesicular monoamine transporter (VMAT1 and VMAT2) in the endocrine pancreas and pancreatic endocrine tumors. J Histochem Cytochem. 2003;51(8):1027–40.PubMed CrossRef
  20.Erickson JD, Schafer MK, Bonner TI, Eiden LE, Weihe E. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci U S A. 1996;93(10):5166–71.PubMed PubMedCentral CrossRef
  21.Peter D, Liu Y, Sternini C, de Giorgio R, Brecha N, Edwards RH. Differential expression of two vesicular monoamine transporters. J Neurosci. 1995;15(9):6179–88.PubMed
  22.Vo KT, Matthay KK, Neuhaus J, London WB, Hero B, Ambros PF, et al. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the International Neuroblastoma Risk Group Project. J Clin Oncol. 2014;32(28):3169–76.PubMed PubMedCentral CrossRef
  23.Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer. 2009;100(9):1471–82.PubMed PubMedCentral CrossRef
  24.Goto S, Umehara S, Gerbing RB, Stram DO, Brodeur GM, Seeger RC, et al. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer. 2001;92(10):2699–708.PubMed CrossRef
  
• 作者单位：William Temple (1) (4)
  Lori Mendelsohn (1) (4)
  Grace E. Kim (2)
  Erin Nekritz (1) (4)
  W. Clay Gustafson (1) (4)
  Lawrence Lin (3)
  Kathy Giacomini (3)
  Arlene Naranjo (5)
  Collin Van Ryn (5)
  Gregory A. Yanik (6)
  Susan G. Kreissman (7)
  Michael Hogarty (8)
  Katherine K. Matthay (1) (4)
  Steven G. DuBois (1) (4) (9)
  
  1. Department of Pediatrics, UCSF School of Medicine, San Francisco, CA, 94143, USA
  4. UCSF Benioff Children’s Hospital, San Francisco, CA, 94158, USA
  2. Department of Pathology, UCSF School of Medicine, San Francisco, CA, 94143, USA
  3. Department of Bioengineering and Therapeutic Sciences, UCSF School of Pharmacy, San Francisco, CA, 94143, USA
  5. Children’s Oncology Group Statistics and Data Center, University of Florida, Gainesville, FL, 32607, USA
  6. CS Mott Children’s Hospital, University of Michigan, Ann Arbor, MI, 48109, USA
  7. Duke University Medical Center, Durham, NC, 27710, USA
  8. Children’s Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA
  9. UCSF School of Medicine, 550 16th Street, 4th Floor, San Francisco, CA, 94158, USA
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Nuclear Medicine
  Imaging and Radiology
  Orthopedics
  Cardiology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1619-7089

文摘

Purpose Vesicular monoamine transporters 1 and 2 (VMAT1 and VMAT2) are thought to mediate MIBG uptake in adult neuroendocrine tumors. In neuroblastoma, the norepinephrine transporter (NET) has been investigated as the principal MIBG uptake protein, though some tumors without NET expression concentrate MIBG. We investigated VMAT expression in neuroblastoma and correlated expression with MIBG uptake and clinical features.